pf-06865571
Small moleculeexperimental
Clinical trial activity
14 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 16, 2017 (NCT03092232)
Timeline
Indications
Mechanism of action
AWAT1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1cccnc1Oc1cncc(-c2ncc(C(=O)N[C@H]3CCOC3)cn2)c1- Mol. weight
- 407.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4760665 ↗
Also known as
- pf-06865571
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05652647 | Phase 1 | Dec 15, 2022 | Pfizer |
| NCT04866225 | Phase 1 | May 11, 2021 | Pfizer |
| NCT04839393 | Phase 1 | Apr 5, 2021 | Pfizer |
| NCT04399538 | Phase 2 | Aug 1, 2020 | Pfizer |
| NCT04321031 | Phase 2 | Jun 15, 2020 | Pfizer |
| NCT04091061 | Phase 1 | Sep 19, 2019 | Pfizer |
| NCT04044053 | Phase 1 | Aug 13, 2019 | Pfizer |
| NCT03776175 | Phase 2 | Jan 4, 2019 | Pfizer |
| NCT03593707 | Phase 1 | Aug 17, 2018 | Pfizer |
| NCT03513588 | Phase 1 | Jun 21, 2018 | Pfizer |
| NCT03534648 | Phase 1 | Apr 19, 2018 | Pfizer |
| NCT03372044 | Phase 1 | Jan 19, 2018 | Pfizer |
| NCT03230383 | Phase 1 | Aug 1, 2017 | Pfizer |
| NCT03092232 | Phase 1 | Mar 16, 2017 | Pfizer |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 14 | 14 | 2 | 2017 |
1 organizations
Page 1 / 1